CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.13BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.03xvs all stocks
52-Week Change
449.72%vs all stocks
Market Capitalization
8.13BUSDvs all stocks (USD)
Enterprise Value
7.25BUSDvs all stocks (USD)
Forward P/E
-27.25xvs Biotechnology peers
Price to Book (MRQ)
8.63xvs Biotechnology peers
Enterprise to EBITDA
-31.60xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-19.81%vs Biotechnology peers
Return on Equity (TTM)
-22.98%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 28, 2026Gross Profit (TTM)
-215.80MUSDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-150.21MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-208.94MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.05MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-219.56MUSDvs all stocks (USD)
Pre-tax Income
-155.22MUSDFY2025 · Dec 31, 2025Income Tax Expense
-15.00KUSDFY2025 · Dec 31, 2025Net Income
-155.20MUSDFY2025 · Dec 31, 2025EBIT
-219.56MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-229.56MUSDFY2025 · Dec 31, 2025Research & Development
171.65MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
47.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
24.89MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.98USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.98USDFY2025 · Dec 31, 2025Basic Shares Outstanding
64.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
64.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-155.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-139.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
-139.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-155.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
37.61MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-29.77MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
7.65MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
7.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-522.21MUSDFY2025 · Dec 31, 2025Sale of Investments
371.74MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-150.47MUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.41MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
305.72MUSDFY2025 · Dec 31, 2025Shares Outstanding
88.06MSharesUpdated Aug 28, 2026Float Shares
82.15MSharesUpdated Aug 28, 2026Shares Short
11.76MSharesUpdated Aug 28, 2026Short Ratio
12.43daysvs all stocks
Short % of Shares Outstanding
14.26%vs all stocks
% Held by Insiders
5.74%vs all stocks
% Held by Institutions
110.68%vs all stocks
Total Cash (MRQ)
1.15BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.99USDUpdated Aug 28, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
18.53xvs Biotechnology peers
Book Value per Share (MRQ)
10.84USDUpdated Aug 28, 2026Total Assets
777.78MUSDvs all stocks (USD)
Total Current Assets
777.78MUSDFY2025 · Dec 31, 2025Total Liabilities
62.55MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.86MUSDFY2025 · Dec 31, 2025Total Current Liabilities
58.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
85.72MUSDFY2025 · Dec 31, 2025Other Short-term Investments
670.81MUSDFY2025 · Dec 31, 2025Accounts Payable
8.90MUSDFY2025 · Dec 31, 2025Other Current Liabilities
23.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.86MUSDFY2025 · Dec 31, 2025Common Stock (Book)
15.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.13BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
715.24MUSDvs all stocks (USD)
52-Week Low
14.51USDUpdated Aug 28, 202652-Week High
110.17USDUpdated Aug 28, 202652-Week Change
449.72%vs all stocks
Beta
3.03xvs all stocks
50-Day MA
98.21USDUpdated Aug 28, 2026200-Day MA
59.67USDUpdated Aug 28, 2026Avg 10-Day Volume
1.05MSharesUpdated Aug 28, 2026Avg 30-Day Volume
926.76KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-1.68USDUpdated Aug 28, 2026Other Income / Expense
39.46MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 194
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 32,166,921.735
Market cap is $8.13B, above the global median of $1.18BNotable
Market cap (USD): 8,129,643,899Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rhythm Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking